Increased immunogenicity of recombinant Ad35-based malaria vaccine through formulation with aluminium phosphate adjuvant

Vaccine

Volumn 25, Issue 35, 2007, Pages 6501-6510

  Ophorst, Olga J A E ^a,b   Radošević, Katarina ^a   Klap, Jaco M ^a   Sijtsma, Jeroen ^a   Gillissen, Gert ^a   Mintardjo, Ratna ^a   van Ooij, Mark J M ^a   Holterman, Lennart ^a   Companjen, Arjen ^a   Goudsmit, Jaap ^a,b   Havenga, Menzo J E ^a  

^a CRUCELL HOLLAND BV   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Ad35 vaccine; Adjuvant; Malaria

Indexed keywords

ADENOVIRUS 35 VACCINE; ALUMINUM PHOSPHATE; MALARIA VACCINE; PROTEIN; RECOMBINANT VACCINE; UNCLASSIFIED DRUG; VIRUS VACCINE;

ABSORPTION; ANIMAL CELL; ARTICLE; B LYMPHOCYTE; DRUG FORMULATION; FEASIBILITY STUDY; FEMALE; HUMAN; HUMAN CELL; IMMUNIZATION; IMMUNOGENICITY; IN VITRO STUDY; MAMMAL CELL; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; T LYMPHOCYTE; VACCINATION; VIRUS INFECTIVITY; VIRUS STRAIN;

ADENOVIRIDAE; ADJUVANTS, IMMUNOLOGIC; ALUMINUM COMPOUNDS; ANIMALS; ANTIBODY FORMATION; CELL SURVIVAL; CHEMISTRY, PHARMACEUTICAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; GENETIC VECTORS; IMMUNITY, CELLULAR; IMMUNIZATION, SECONDARY; MALARIA VACCINES; MICE; MICE, INBRED BALB C; PHOSPHATES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; VACCINES, SYNTHETIC;

EID: 34547589548     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2007.06.019     Document Type: Article

References (53)

1. Schofield L., Villaquiran J., Ferreira A., Schellekens H., Nussenzweig R., and Nussenzweig V. Gamma interferon, CD8+ T cells and antibodies required for immunity to malaria sporozoites. Nature 330 6149 (1987) 664-666
2. Egan J.E., Weber J.L., Ballou W.R., Hollingdale M.R., Majarian W.R., Gordon D.M., et al. Efficacy of murine malaria sporozoite vaccines: implications for human vaccine development. Science 236 4800 (1987) 453-456
3. Gwadz R.W., Cochrane A.H., Nussenzweig V., and Nussenzweig R.S. Preliminary studies on vaccination of rhesus monkeys with irradiated sporozoites of Plasmodium knowlesi and characterization of surface antigens of these parasites. Bull World Health Organ 57 Suppl 1 (1979) 165-173
4. Nussenzweig R.S., Vanderberg J.P., Most H., and Orton C. Specificity of protective immunity produced by X-irradiated Plasmodium berghei sporozoites. Nature 222 5192 (1969) 488-489
5. Clyde D.F., McCarthy V.C., Miller R.M., and Hornick R.B. Specificity of protection of man immunized against sporozoite-induced falciparum malaria. Am J Med Sci 266 6 (1973) 398-403
6. Rieckmann K.H., Carson P.E., Beaudoin R.L., Cassells J.S., and Sell K.W. Letter: sporozoite induced immunity in man against an Ethiopian strain of Plasmodium falciparum. Trans R Soc Trop Med Hyg 68 3 (1974) 258-259
7. Herrington D., Davis J., Nardin E., Beier M., Cortese J., Eddy H., et al. Successful immunization of humans with irradiated malaria sporozoites: humoral and cellular responses of the protected individuals. Am J Trop Med Hyg 45 5 (1991) 539-547
8. Edelman R., Hoffman S.L., Davis J.R., Beier M., Sztein M.B., Losonsky G., et al. Long-term persistence of sterile immunity in a volunteer immunized with X-irradiated Plasmodium falciparum sporozoites. J Infect Dis 168 4 (1993) 1066-1070
9. Egan J.E., Hoffman S.L., Haynes J.D., Sadoff J.C., Schneider I., Grau G.E., et al. Humoral immune responses in volunteers immunized with irradiated Plasmodium falciparum sporozoites. Am J Trop Med Hyg 49 2 (1993) 166-173
10. Herrington D.A., Losonsky G.A., Smith G., Volvovitz F., Cochran M., Jackson K., et al. Safety and immunogenicity in volunteers of a recombinant Plasmodium falciparum circumsporozoite protein malaria vaccine produced in Lepidopteran cells. Vaccine 10 12 (1992) 841-846
11. Hoffman S.L., Edelman R., Bryan J.P., Schneider I., Davis J., Sedegah M., et al. Safety, immunogenicity, and efficacy of a malaria sporozoite vaccine administered with monophosphoryl lipid A, cell wall skeleton of mycobacteria, and squalane as adjuvant. Am J Trop Med Hyg 51 5 (1994) 603-612
12. Gonzalez C., Hone D., Noriega F.R., Tacket C.O., Davis J.R., Losonsky G., et al. Salmonella typhi vaccine strain CVD 908 expressing the circumsporozoite protein of Plasmodium falciparum: strain construction and safety and immunogenicity in humans. J Infect Dis 169 4 (1994) 927-931
13. Stoute J.A., Slaoui M., Heppner D.G., Momin P., Kester K.E., Desmons P., et al. A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group. N Engl J Med 336 2 (1997) 86-91
14. Bojang K.A., Milligan P.J., Pinder M., Vigneron L., Alloueche A., Kester K.E., et al. Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial. Lancet 358 9297 (2001) 1927-1934
15. Alonso P.L., Sacarlal J., Aponte J.J., Leach A., Macete E., Milman J., et al. Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial. Lancet 364 9443 (2004) 1411-1420
16. Weiss W.R., Sedegah M., Beaudoin R.L., Miller L.H., and Good M.F. CD8+ T cells (cytotoxic/suppressors) are required for protection in mice immunized with malaria sporozoites. Proc Natl Acad Sci USA 85 2 (1988) 573-576
17. Romero P., Maryanski J.L., Corradin G., Nussenzweig R.S., Nussenzweig V., and Zavala F. Cloned cytotoxic T cells recognize an epitope in the circumsporozoite protein and protect against malaria. Nature 341 6240 (1989) 323-326
18. Rodrigues M.M., Cordey A.S., Arreaza G., Corradin G., Romero P., Maryanski J.L., et al. CD8+ cytolytic T cell clones derived against the Plasmodium yoelii circumsporozoite protein protect against malaria. Int Immunol 3 6 (1991) 579-585
19. Khusmith S., Charoenvit Y., Kumar S., Sedegah M., Beaudoin R.L., and Hoffman S.L. Protection against malaria by vaccination with sporozoite surface protein 2 plus CS protein. Science 252 5006 (1991) 715-718
20. Rodrigues E.G., Zavala F., Eichinger D., Wilson J.M., and Tsuji M. Single immunizing dose of recombinant adenovirus efficiently induces CD8+ T cell-mediated protective immunity against malaria. J Immunol 158 3 (1997) 1268-1274
21. Rodrigues E.G., Zavala F., Nussenzweig R.S., Wilson J.M., and Tsuji M. Efficient induction of protective anti-malaria immunity by recombinant adenovirus. Vaccine 16 19 (1998) 1812-1817
22. Rodrigues E.G., Claassen J., Lee S., Wilson J.M., Nussenzweig R.S., and Tsuji M. Interferon-gamma-independent CD8+ T cell-mediated protective anti-malaria immunity elicited by recombinant adenovirus. Parasite Immunol 22 3 (2000) 157-160
23. Bruna-Romero O., Rocha C.D., Tsuji M., and Gazzinelli R.T. Enhanced protective immunity against malaria by vaccination with a recombinant adenovirus encoding the circumsporozoite protein of Plasmodium lacking the GPI-anchoring motif. Vaccine 22 27/28 (2004) 3575-3584
24. Ophorst O.J., Radosevic K., Havenga M.J., Pau M.G., Holterman L., Berkhout B., et al. Immunogenicity and protection of a recombinant human adenovirus serotype 35-based malaria vaccine against Plasmodium yoelii in mice. Infect Immun 74 1 (2006) 313-320
25. Santra S., Seaman M.S., Xu L., Barouch D.H., Lord C.I., Lifton M.A., et al. Replication-defective adenovirus serotype 5 vectors elicit durable cellular and humoral immune responses in nonhuman primates. J Virol 79 10 (2005) 6516-6522
26. Casimiro D.R., Chen L., Fu T.M., Evans R.K., Caulfield M.J., Davies M.E., et al. Comparative immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia virus, and replication-defective adenovirus vectors expressing a human immunodeficiency virus type 1 gag gene. J Virol 77 11 (2003) 6305-6313
27. Catanzaro A.T., Koup R.A., Roederer M., Bailer R.T., Enama M.E., Moodie Z., et al. Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector. J Infect Dis 194 12 (2006) 1638-1649
28. Duerr A., Wasserheit J.N., and Corey L. HIV vaccines: new frontiers in vaccine development. Clin Infect Dis 43 4 (2006) 500-511
29. Kostense S., Koudstaal W., Sprangers M., Weverling G.J., Penders G., Helmus N., et al. Adenovirus types 5 and 35 seroprevalence in AIDS risk groups supports type 35 as a vaccine vector. AIDS 18 8 (2004) 1213-1216
30. Nwanegbo E., Vardas E., Gao W., Whittle H., Sun H., Rowe D., et al. Prevalence of neutralizing antibodies to adenoviral serotypes 5 and 35 in the adult populations of The Gambia, South Africa, and the United States. Clin Diagn Lab Immunol 11 2 (2004) 351-357
31. Thorner A.R., Vogels R., Kaspers J., Weverling G.J., Holterman L., Lemckert A.A., et al. Age dependence of adenovirus-specific neutralizing antibody titers in individuals from sub-Saharan Africa. J Clin Microbiol 44 10 (2006) 3781-3783
32. de Gruijl T.D., Ophorst O.J., Goudsmit J., Verhaagh S., Lougheed S.M., Radosevic K., et al. Intradermal delivery of adenoviral type-35 vectors leads to high efficiency transduction of mature, CD8+ T cell-stimulating skin-emigrated dendritic cells. J Immunol 177 4 (2006) 2208-2215
33. Verhaagh S., de Jong E., Goudsmit J., Lecollinet S., Gillissen G., de Vries M., et al. Human CD46-transgenic mice in studies involving replication-incompetent adenoviral type 35 vectors. J Gen Virol 87 Pt 2 (2006) 255-265
34. Abbink P., Lemckert A.A., Ewald B.A., Lynch D.M., Denholtz M., Smits S., et al. Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D. J Virol (2007)
35. Havenga M., Vogels R., Zuijdgeest D., Radosevic K., Mueller S., Sieuwerts M., et al. Novel replication-incompetent adenoviral B-group vectors: high vector stability and yield in PER.C6 cells. J Gen Virol 87 Pt 8 (2006) 2135-2143
36. Barouch D.H., Pau M.G., Custers J.H., Koudstaal W., Kostense S., Havenga M.J., et al. Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity. J Immunol 172 10 (2004) 6290-6297
37. Ophorst O.J., Radosevic K., Ouwehand K., van Beem W., Mintardjo R., Sijtsma J., et al. Expression and immunogenicity of the Plasmodium falciparum circumsporozoite protein: the role of GPI signal sequence. Vaccine 25 8 (2007) 1426-1436
38. Sprangers M.C., Lakhai W., Koudstaal W., Verhoeven M., Koel B.F., Vogels R., et al. Quantifying adenovirus-neutralizing antibodies by luciferase transgene detection: addressing preexisting immunity to vaccine and gene therapy vectors. J Clin Microbiol 41 11 (2003) 5046-5052
39. Cox J.C., and Coulter A.R. Adjuvants-a classification and review of their modes of action. Vaccine 15 3 (1997) 248-256
40. Wang S., Liu X., Fisher K., Smith J.G., Chen F., Tobery T.W., et al. Enhanced type I immune response to a hepatitis B DNA vaccine by formulation with calcium- or aluminum-phosphate. Vaccine 18 13 (2000) 1227-1235
41. WHO (World Health Organization). Immunological adjuvants. Technical Report Series, No. 595. Geneva: World Health Organization; 1976, p. 6-8.
42. Aprile M.A., and Wardlaw A.C. Aluminium compounds as adjuvants for vaccines and toxoids in man: a review. Can J Public Health 57 8 (1966) 343-360
43. Chang M., Shi Y., Nail S.L., HogenEsch H., Adams S.B., White J.L., et al. Degree of antigen adsorption in the vaccine or interstitial fluid and its effect on the antibody response in rabbits. Vaccine 19 20-22 (2001) 2884-2889
44. Shi Y., HogenEsch H., and Hem S.L. Change in the degree of adsorption of proteins by aluminum-containing adjuvants following exposure to interstitial fluid: freshly prepared and aged model vaccines. Vaccine 20 1/2 (2001) 80-85
45. Iyer S., Robinett R.S., HogenEsch H., and Hem S.L. Mechanism of adsorption of hepatitis B surface antigen by aluminum hydroxide adjuvant. Vaccine 22 11/12 (2004) 1475-1479
46. Morefield G.L., Jiang D., Romero-Mendez I.Z., Geahlen R.L., Hogenesch H., and Hem S.L. Effect of phosphorylation of ovalbumin on adsorption by aluminum-containing adjuvants and elution upon exposure to interstitial fluid. Vaccine 23 12 (2005) 1502-1506
47. Jiang D., Morefield G.L., HogenEsch H., and Hem S.L. Relationship of adsorption mechanism of antigens by aluminum-containing adjuvants to in vitro elution in interstitial fluid. Vaccine 24 10 (2006) 1665-1669
48. Ulmer J.B., DeWitt C.M., Chastain M., Friedman A., Donnelly J.J., McClements W.L., et al. Enhancement of DNA vaccine potency using conventional aluminum adjuvants. Vaccine 18 1/2 (1999) 18-28
49. Gupta R.K. Aluminum compounds as vaccine adjuvants. Adv Drug Deliv Rev 32 3 (1998) 155-172
50. Morefield G.L., Sokolovska A., Jiang D., HogenEsch H., Robinson J.P., and Hem S.L. Role of aluminum-containing adjuvants in antigen internalization by dendritic cells in vitro. Vaccine 23 13 (2005) 1588-1595
51. Ulanova M., Tarkowski A., Hahn-Zoric M., and Hanson L.A. The Common vaccine adjuvant aluminum hydroxide up-regulates accessory properties of human monocytes via an interleukin-4-dependent mechanism. Infect Immun 69 2 (2001) 1151-1159
52. Rimaniol A.C., Gras G., Verdier F., Capel F., Grigoriev V.B., Porcheray F., et al. Aluminum hydroxide adjuvant induces macrophage differentiation towards a specialized antigen-presenting cell type. Vaccine 22 23/24 (2004) 3127-3135
53. Flarend R.E., Hem S.L., White J.L., Elmore D., Suckow M.A., Rudy A.C., et al. In vivo absorption of aluminium-containing vaccine adjuvants using 26Al. Vaccine 15 12/13 (1997) 1314-1318